Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Britannia Life Sciences Inc Com C.RLSC

RISE Life Science Corp is engaged in developing and evolving medical and adult hemp-based formulations to create general use of health and well-being products for the emerging consumer category. It derives key revenue from the United States.


CSE:RLSC - Post by User

Post by NostraDAMNuson Aug 03, 2020 9:42pm
324 Views
Post# 31359189

JULY 28 SEDAR

JULY 28 SEDAR
https://www.sedar.com/GetFile.do?lang=EN&docClass=7&issuerNo=00015710&issuerType=03&projectNo=03088008&docId=4767721

Escrow Release Conditions Upon the satisfaction of the following conditions (the “Escrow Release Conditions”), to be completed within 180 days from the date of closing, the escrow agent shall release the Escrowed Funds (defined below) to the Company. - All current outstanding debt, not including trade payables, of the Company shall be exchanged for Resulting Issuer Shares based on a conversion price of C$0.075 per share; - All current interest payable by RISE shall be exchanged for Resulting Issuer Shares based on a conversion price of C$0.05 per share; - Written confirmation from RISE that there are no ongoing debt obligations, not including trade payables, or interestbearing liabilities associated with the Company; - Written confirmation from each of the Company and Scientus that all conditions to the completion of the Transaction have been satisfied or waived, including the assignment and amendment of the Scientus Debt (as defined below), other than the release of the Escrowed Funds; - The receipt of audited financial statements of Scientus for the years ended December 31, 2018 and December 31, 2019; - The Resulting Issuer Shares being approved for listing on the CSE; and - The receipt of all regulatory, shareholder and third-party approvals, if any, required in connection with the Transaction

IS THE 3rd PARTY....COBRA VENTURES??? Deal may still be in effect, we will know soon enough.
<< Previous
Bullboard Posts
Next >>